Redenlab is pleased to announce that Dr. Adam Vogel, an expert in speech and language function, will be presenting at...
Dr. Adam Vogel, CSO of Redenlab, will be speaking alongside Dr. Tairmae Kangarloo, Associate Director of Digital Strategy at Takeda,...
Redenlab is proud to announce our participation in the 14th International Conference on Frontotemporal Dementias (ICFTD), to be held in...
This video features an interview hosted by Global Health Youth Connect with Professor Adam Vogel called Interview with Experts.The conversation...
Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.